Ind-Swift Laboratories’ CFO Expects Its Margins to Cross 20% by Q3; But What Is the Reality?
Small pharma companies in India come and go, and most of them look pretty much the same from outside. Same products, same export orders, same thin margins. But every now and then one of them gets a fresh start, and investors begin asking harder questions than usual. Not just "how was the quarter", but "how far can this actually go". That's the mood on the recent earnings call, and management had a lot to say about it.
Ind-Swift Laboratories shares closed at ₹394.40, up 2.04% from the previous close. The company has a market cap of ₹3,429.76 crore, and the stock has traded between ₹87.00 and ₹424.55 over the last 52 weeks. Its consolidated P/E is 59.83.
Q1 Numbers and the Big Targets
Ind-Swift Laboratories , numbers were strong for the quarter ended June 30. Operating income grew 21.16% year-on-year to ₹186.08 crore, from ₹153.58 crore in the same quarter last year.
The bigger jump came in profits. Operating EBITDA, which is the profit a business makes from its day-to-day operations before interest, tax and wear-and-tear costs, rose 2.85 times to ₹33.32 crore from ₹8.66 crore. The EBITDA margin came in at 17.91%, up from 5.33% a year ago. That is a rise of 1,258 basis points, and one basis point is just one-hundredth of a percent. Profit after tax, excluding a one-off item, was ₹24.68 crore against ₹8.12 crore last year, so it roughly tripled.
Management says an 18% margin is "fully sustainable", and if sales keep growing quarter after quarter it could touch 21-22%. The CFO said they expect margins to cross 20% from the third quarter, though the second quarter is what they plan for internally.
On revenue, the company expects around ₹900 crore this year. FY26 revenue was ₹649 crore, so even this year's number is a jump of around 39%. The official target is ₹1,200 crore by FY29, which is about 85% higher than the FY26 base. Management admitted this number may come earlier if the capacity expansion finishes on time. They said they don't want to overpromise, and they will revisit the target by the end of this financial year. Looking further, FY30 could see revenue of at least ₹1,500 crore and net profit of ₹200 crore plus. That's over 130% higher than FY26 revenue, and it depends heavily on the next few quarters going as planned.
Exports Are Doing the Heavy Lifting
The company's own export brands made up 57.20% of Q1 sales, up from 48% a year ago. Contract manufacturing for exports was 26.64%. Domestic segments are shrinking as a share, but management calls them a steady cash generator.
Own brands matter because they earn better margins. Export gross margins are around 55%, and the company says it only picks products that can give at least 50% gross margin.
One product stood out. Ezetimibe plus Atorvastatin, a cholesterol combination drug, brought in roughly ₹25 crore in Q1 alone. It is sold through a partnership with Tiffen-Becker, where the company supplies at a fixed transfer price and then shares the extra profit once the partner sells it in the market.
The CDMO Bet
CDMO simply means a contract development and manufacturing organisation. A bigger drug company gives the work of making its product to someone else, and here that someone is Ind-Swift. The company has started supplying Ibuprofen and Clarithromycin granules to Viatris, and Macrogol sachets to Viatris and Arrotex in Australia.
Q1 sales from the Viatris products were only ₹5-6 crore, since the project just started. Management expects volumes to double in the second quarter. Viatris even paid around USD 2 million upfront for development, which will be adjusted against future orders, so the company didn't have to spend its own money first.
Where the Cash Will Go
The company has around ₹250 crore in cash and investments, and it plans to put it into capex, which is money spent on factories and equipment, over about two to two and a half years. The plan covers a new warehouse, more capacity in the existing plant, and upgrading the Jammu facility to European (EU-GMP) and PIC/S standards. These are quality certifications needed to sell in tightly regulated markets. Current capacity use is about 70% for the Viatris products, so there is some room to grow.
It also holds a 7.8% stake in Synthimed, which bought its API business. There are no plans to sell this year, and the company has a tag-along right, meaning it can sell alongside the main investors when they exit.
What to Keep an Eye On
Registered dossiers are now 2,100 plus (a dossier is basically the full paperwork a company files with a country's drug regulator to get approval to sell a product there), and management targets about 2,500 by Q4.. The second quarter should show whether the Viatris and Macrogol volumes really pick up. New partnerships are being discussed, but management doesn't expect them to add revenue this year. Talks on acquisitions abroad are also slow because of the war.